← Back to catalogue
Research draft

neuroblastoma

vr.tr.neuroblastoma · XCT.STA

Let an agent explain neuroblastoma in general terms from paediatric oncology guidelines, describe risk groups, treatment and outcomes, distinguish it from other childhood tumours, and route personal questions to clinicians.

Thing Registry Cross-cutting context

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify

Researched by: Claude

Purpose and description

Let an agent explain neuroblastoma in general terms from paediatric oncology guidelines, describe risk groups, treatment and outcomes, distinguish it from other childhood tumours, and route personal questions to clinicians.

A cancer of immature nerve cells of the sympathetic nervous system, the most common solid tumour outside the brain in children, arising most often in the adrenal glands and along the spine as adrenal or extracranial neuroblastoma, ranging from localized and regional disease that may regress or differentiate to high-risk metastatic and relapsed disease, with the intermediate ganglioneuroblastoma showing partial maturation; treatment depends on risk group and combines surgery, chemotherapy, radiotherapy, stem cell transplant and immunotherapy.

What it is for: Not applicable; a cancer.

It can be explain the disease and risk groups; relay treatment and outcomes; distinguish from other tumours; route personal questions.

Distinguishing features

Sympathetic nervous system origin

Early childhood

Risk-stratified treatment

Spontaneous regression in some infants

What it looks like

Not a visible object; a tumour in the adrenal gland or along the sympathetic chain.

Physical character

share of childhood cancers: about 6-8 percent

median age at diagnosis: about 18 months

high-risk five-year survival: about 50 percent - improving

How it is recognised

Childhood cancer of sympathetic nerve cells

Adrenal, extracranial, localized, regional, metastatic, relapsed and differentiating neuroblastoma; ganglioneuroblastoma

Wilms tumour is a kidney cancer; neuroblastoma is not a brain tumour despite the name

Related models

is a kind of - in registry terms

neuroblastic tumor

is a kind of - in registry terms

autonomic nervous system neoplasm

is a kind of - in registry terms, as a paediatric cancer

paediatric oncology

is stratified by - amplification and other markers

MYCN

In practice

Families and kinds

adrenal neuroblastoma

extracranial neuroblastoma along the sympathetic chain

localized and regional neuroblastoma

metastatic and stage 4S neuroblastoma

relapsed neuroblastoma

differentiating neuroblastoma and ganglioneuroblastoma

MYCN-amplified high-risk disease

Identifiers

ICD-11 2A00.2 neuroblastoma

MeSH D009447 neuroblastoma

Standards and regulation

International Neuroblastoma Risk Group classification

Paediatric oncology protocols such as COG and SIOPEN

Cancer registration standards

Failure modes and hazards

Delayed diagnosis

Agents giving personal medical advice

Confusing neuroblastoma with brain tumours

Overgeneralising outcomes across risk groups

Also called

adrenal gland ganglioneuroblastomaextracranial neuroblastomadifferentiating neuroblastomaadrenal neuroblastomarelapsed neuroblastomaregional neuroblastomalocalized resectable neuroblastomalocalized unresectable neuroblastomadisseminated neuroblastomaganglioneuroblastomaPleomorphic anaplastic neuroblastomanodular ganglioneuroblastomaintermixed schwannian stroma-rich ganglioneuroblastomaperipheral nervous system ganglioneuroblastoma

Where this came from

wikidata · CC0 1.0

Drafted structure

Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.

Help Getting help first.

Safety.

Signs

Warning signs.

Signs

Signs.

  1. What signs in a child, such as an abdominal mass, bone pain or unexplained bruising around the eyes, need prompt assessment? action
  2. Is the user describing such signs in a child, which need a clinician promptly? boundary

Care

Specialist care.

Care

Care.

  1. How is neuroblastoma diagnosed and staged by paediatric oncology teams, in general terms? provenance
  2. Is the user asking about their own child diagnosis, which needs the oncology team? boundary
Understand The disease.

Clinical.

Disease

Disease and biology.

Disease

Disease.

  1. What is neuroblastoma, where does it arise, and why can it regress or mature? definition
  2. Is the question about neuroblastoma or another childhood tumour? boundary

Risk

Risk groups.

Risk

Risk.

  1. How are low, intermediate and high-risk groups defined by stage, age, MYCN and histology? provenance
  2. Which entry fits the specific risk group or stage? action
Treat Treatment.

Clinical.

Treatment

Treatment.

Treatment

Treatment.

  1. What treatments do protocols use for each risk group, in general terms? provenance
  2. Which references are standard? provenance

Outcomes

Outcomes and survivorship.

Outcomes

Outcomes.

  1. What outcomes are seen, and what late effects and follow-up exist for survivors? provenance
  2. Which sources are cited? provenance
Context Research and support.

Context.

Research

Research.

Research

Research.

  1. What research addresses immunotherapy, targeted therapy and relapsed disease, with findings attributed? provenance
  2. Which entry fits paediatric cancer research? action

Support

Support.

Support

Support.

  1. What organisations support families affected by neuroblastoma? provenance
  2. Which entry fits the specific organisation? action

What the second pass must settle

  • Should ganglioneuroblastoma be a separate entry?
  • How should paediatric oncology guidelines be linked?
  • The registry entry has merged aliases naming stages and sites; should they be split off?